2025 CPT code 0064U
Effective Date: N/A Proprietary Laboratory Analyses Feed
Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative.
Medical necessity is established by the patient's symptoms, risk factors, or need to monitor treatment response for syphilis. Refer to specific payer guidelines for coverage details.
The lab analyst performs the immunoassay on a patient specimen, typically serum, to detect and quantify both treponemal and RPR antibodies. Results are used by clinicians to diagnose or manage syphilis treatment.
In simple words: This test checks for syphilis by looking for two types of antibodies in a blood sample. It's a single test that gives more complete information than older methods that required two separate tests.
BioPlex™ 2200 Syphilis Total & RPR Assay, from Bio–Rad® Laboratories, a single immunoassay panel to evaluate both total treponemal antibody and non-treponemal antibody rapid plasma reagin (RPR) in a patient specimen to aid in syphilis diagnosis or treatment management.
Example 1: A patient presents with symptoms suggestive of syphilis. This test is ordered to provide a comprehensive assessment of both treponemal and RPR antibodies, aiding in diagnosis., A patient with a history of syphilis is being monitored for treatment response. This test is used to track changes in RPR antibody levels, which typically decline with successful treatment., A patient has a positive treponemal antibody test (86780). This test is then used as a confirmatory test, simultaneously providing RPR information for a more complete picture.
Documentation should include the reason for testing, the patient's signs and symptoms, and relevant medical history. The specimen type and date of collection should also be documented.
- Specialties:Infectious Disease, Internal Medicine, Family Medicine, Obstetrics and Gynecology, Pediatrics
- Place of Service:Office, Independent Laboratory, Hospital Outpatient